JP2005539068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005539068A5 JP2005539068A5 JP2004536572A JP2004536572A JP2005539068A5 JP 2005539068 A5 JP2005539068 A5 JP 2005539068A5 JP 2004536572 A JP2004536572 A JP 2004536572A JP 2004536572 A JP2004536572 A JP 2004536572A JP 2005539068 A5 JP2005539068 A5 JP 2005539068A5
- Authority
- JP
- Japan
- Prior art keywords
- dichlorophenyl
- formula
- formamide
- tetrahydronaphthalen
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 37
- 208000015114 central nervous system disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 208000019022 Mood disease Diseases 0.000 claims description 5
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 5
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 3
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims description 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 3
- 201000009032 substance abuse Diseases 0.000 claims description 3
- 231100000736 substance abuse Toxicity 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 15
- 208000012902 Nervous system disease Diseases 0.000 claims 14
- SRPXSILJHWNFMK-UHFFFAOYSA-N norsertraline Chemical compound C12=CC=CC=C2C(N)CCC1C1=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-UHFFFAOYSA-N 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 12
- QTQHFJQQMCUQEY-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C1C2=CC=CC=C2C(NC=O)CC1 QTQHFJQQMCUQEY-UHFFFAOYSA-N 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- QTQHFJQQMCUQEY-SJKOYZFVSA-N n-[(1r,4r)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@@H]1C2=CC=CC=C2[C@H](NC=O)CC1 QTQHFJQQMCUQEY-SJKOYZFVSA-N 0.000 claims 7
- QTQHFJQQMCUQEY-YVEFUNNKSA-N n-[(1r,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@H]1C2=CC=CC=C2[C@H](NC=O)CC1 QTQHFJQQMCUQEY-YVEFUNNKSA-N 0.000 claims 7
- 208000028017 Psychotic disease Diseases 0.000 claims 6
- JGMBHJNMQVKDMW-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1C2=CC=CC=C2C(=O)CC1 JGMBHJNMQVKDMW-UHFFFAOYSA-N 0.000 claims 5
- QTQHFJQQMCUQEY-PXAZEXFGSA-N n-[(1s,4r)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@@H]1C2=CC=CC=C2[C@@H](NC=O)CC1 QTQHFJQQMCUQEY-PXAZEXFGSA-N 0.000 claims 5
- QTQHFJQQMCUQEY-SJCJKPOMSA-N n-[(1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@H]1C2=CC=CC=C2[C@@H](NC=O)CC1 QTQHFJQQMCUQEY-SJCJKPOMSA-N 0.000 claims 5
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 4
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims 2
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000019253 formic acid Nutrition 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 239000011260 aqueous acid Substances 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 208000035548 disruptive behavior disease Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003982 neuronal uptake Effects 0.000 description 3
- 0 *c1cc(C(CC2)c3ccccc3[C@]2N)ccc1Cl Chemical compound *c1cc(C(CC2)c3ccccc3[C@]2N)ccc1Cl 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- PUKBOMXODMUDBW-CQSZACIVSA-N Clc1ccc([C@@H]2c3ccccc3CCC2)cc1Cl Chemical compound Clc1ccc([C@@H]2c3ccccc3CCC2)cc1Cl PUKBOMXODMUDBW-CQSZACIVSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 208000007656 osteochondritis dissecans Diseases 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41130402P | 2002-09-16 | 2002-09-16 | |
| US41130502P | 2002-09-16 | 2002-09-16 | |
| PCT/US2003/029110 WO2004024669A1 (en) | 2002-09-16 | 2003-09-16 | Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005539068A JP2005539068A (ja) | 2005-12-22 |
| JP2005539068A5 true JP2005539068A5 (enExample) | 2007-03-22 |
| JP4610336B2 JP4610336B2 (ja) | 2011-01-12 |
Family
ID=31998027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004536572A Expired - Fee Related JP4610336B2 (ja) | 2002-09-16 | 2003-09-16 | トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドによる中枢神経系障害の治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US7087785B2 (enExample) |
| EP (1) | EP1542961B1 (enExample) |
| JP (1) | JP4610336B2 (enExample) |
| KR (2) | KR101067045B1 (enExample) |
| CN (1) | CN101712626B (enExample) |
| AU (1) | AU2003272460B2 (enExample) |
| BR (1) | BRPI0314377B8 (enExample) |
| CA (1) | CA2498152C (enExample) |
| DK (1) | DK1542961T3 (enExample) |
| ES (1) | ES2431519T3 (enExample) |
| IL (1) | IL167319A (enExample) |
| MX (1) | MXPA05002700A (enExample) |
| NZ (1) | NZ538741A (enExample) |
| PT (1) | PT1542961E (enExample) |
| WO (1) | WO2004024669A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0314377B8 (pt) | 2002-09-16 | 2021-05-25 | Sepracor Inc | composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto |
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| EP2343073A3 (en) * | 2003-12-11 | 2011-10-12 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| AU2004312530A1 (en) * | 2003-12-29 | 2005-07-21 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
| US20060199739A1 (en) * | 2005-03-02 | 2006-09-07 | Olav Messerschmidt | Limonene-containing herbicide compositions, herbicide concentrate formulations and methods for making and using same |
| WO2007006003A2 (en) * | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| WO2007075173A1 (en) * | 2005-12-29 | 2007-07-05 | Utc Power Corporation | Circulation of gas-entrained fuel cell coolant |
| ES2566479T3 (es) * | 2006-01-06 | 2016-04-13 | Sunovion Pharmaceuticals Inc. | Inhibidores de reabsorción de monoamina con base en tetralona |
| KR101294014B1 (ko) * | 2006-01-06 | 2013-08-09 | 선오비온 파마슈티컬스 인코포레이티드 | 모노아민 재흡수 저해제로서의 시클로알킬아민 |
| EP2816024B8 (en) * | 2006-03-31 | 2018-04-04 | Sunovion Pharmaceuticals Inc. | Chiral amines |
| AU2013211500B2 (en) * | 2006-03-31 | 2016-08-04 | Sepracor Inc | Preparation of chiral amides and amines |
| JP2009538925A (ja) * | 2006-05-31 | 2009-11-12 | セプラコール， インク． | ｔｒａｎｓ４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドを用いる疼痛性障害の治療 |
| US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| BRPI0717171B1 (pt) * | 2006-09-25 | 2023-10-17 | Archer Daniels Midland Company | Material superabsorvente |
| US20080082066A1 (en) * | 2006-10-02 | 2008-04-03 | Weyerhaeuser Co. | Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks |
| US8138377B2 (en) * | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| FR2909376A1 (fr) * | 2006-11-30 | 2008-06-06 | Cerep Sa | Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| ZA200904686B (en) * | 2007-01-18 | 2010-09-29 | Sepracor Inc | Inhibitiors of D-amino acid oxidase |
| CN101686672A (zh) | 2007-05-31 | 2010-03-31 | 塞普拉柯公司 | 苯基取代的环烷胺作为一元胺再摄取抑制剂 |
| WO2010017418A1 (en) * | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| CN102573823B (zh) * | 2009-05-13 | 2015-01-07 | 桑诺维恩药品公司 | 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途 |
| US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| CA2782240A1 (en) * | 2009-12-04 | 2011-06-09 | Sunovion Pharmaceuticals Inc. | Formulations, salts and polymorphs of transnorsertraline and uses thereof |
| US8883815B2 (en) | 2011-05-19 | 2014-11-11 | Gilrose Pharmaceuticals, Llc | Treatment for cerebral palsy impaired speech in children |
| US20140163070A1 (en) | 2012-05-17 | 2014-06-12 | Bruce Roseman | Treatment for cerebral palsy impaired speech in children |
| US9682073B2 (en) | 2011-05-19 | 2017-06-20 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| US10085414B2 (en) | 2011-05-19 | 2018-10-02 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder speech, gait and limb impairments treatment |
| US9220712B2 (en) | 2011-05-19 | 2015-12-29 | Gilrose Pharmaceuticals, Llc | Pharmaceutical intervention and method for treating an apraxia of speech in children |
| WO2012158892A2 (en) | 2011-05-19 | 2012-11-22 | Bruce Roseman | A method of treating apraxia of speech in children |
| JP2017515849A (ja) * | 2014-05-13 | 2017-06-15 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | Ａｄｈｄを治療するためのダソトラリン用量および治療方法 |
| EP3142999A4 (en) * | 2014-05-13 | 2017-12-27 | Sunovion Pharmaceuticals Inc. | Methods and compositions of dasotraline for treatment of adhd |
| WO2016046669A2 (en) * | 2014-09-27 | 2016-03-31 | Mohan M Alapati | Compositions and methods for the treatment of depression and neurological diseases |
| US20200405867A1 (en) * | 2018-01-19 | 2020-12-31 | Sunovion Pharmaceuticals Inc. | Oral dosage forms |
| WO2020092496A1 (en) | 2018-10-31 | 2020-05-07 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
| EP3800178A1 (en) | 2019-10-01 | 2021-04-07 | Moehs Ibérica, S.L. | Preparation of enamide intermediate for the synthesis of dasotraline |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4556676A (en) * | 1979-11-01 | 1985-12-03 | Pfizer Inc. | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| JPS59497B2 (ja) * | 1979-11-01 | 1984-01-07 | フアイザ−・インコ−ポレ−テツド | トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体 |
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
| US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| US5778986A (en) * | 1997-08-05 | 1998-07-14 | Davis; Floyd A. | Device to remove divots |
| US6245782B1 (en) * | 1999-05-17 | 2001-06-12 | Heartdrug Research L.L.C. | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
| BRPI0314377B8 (pt) * | 2002-09-16 | 2021-05-25 | Sepracor Inc | composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto |
-
2003
- 2003-09-16 BR BRPI0314377A patent/BRPI0314377B8/pt not_active IP Right Cessation
- 2003-09-16 CA CA2498152A patent/CA2498152C/en not_active Expired - Fee Related
- 2003-09-16 CN CN2009102541788A patent/CN101712626B/zh not_active Expired - Fee Related
- 2003-09-16 ES ES03754641T patent/ES2431519T3/es not_active Expired - Lifetime
- 2003-09-16 US US10/663,173 patent/US7087785B2/en not_active Expired - Lifetime
- 2003-09-16 NZ NZ538741A patent/NZ538741A/en not_active IP Right Cessation
- 2003-09-16 PT PT37546413T patent/PT1542961E/pt unknown
- 2003-09-16 DK DK03754641.3T patent/DK1542961T3/da active
- 2003-09-16 KR KR1020057004420A patent/KR101067045B1/ko not_active Expired - Fee Related
- 2003-09-16 AU AU2003272460A patent/AU2003272460B2/en not_active Ceased
- 2003-09-16 WO PCT/US2003/029110 patent/WO2004024669A1/en not_active Ceased
- 2003-09-16 EP EP03754641.3A patent/EP1542961B1/en not_active Expired - Lifetime
- 2003-09-16 MX MXPA05002700A patent/MXPA05002700A/es active IP Right Grant
- 2003-09-16 KR KR1020117017571A patent/KR101165549B1/ko not_active Expired - Fee Related
- 2003-09-16 JP JP2004536572A patent/JP4610336B2/ja not_active Expired - Fee Related
-
2005
- 2005-03-08 IL IL167319A patent/IL167319A/en active IP Right Grant
- 2005-09-07 US US11/220,891 patent/US7105699B2/en not_active Expired - Lifetime
-
2006
- 2006-01-24 US US11/338,191 patent/US20060128993A1/en not_active Abandoned
- 2006-05-03 US US11/416,586 patent/US7423179B2/en not_active Expired - Lifetime
-
2008
- 2008-07-15 US US12/173,626 patent/US7589237B2/en not_active Expired - Lifetime
-
2009
- 2009-08-10 US US12/538,583 patent/US7790772B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005539068A5 (enExample) | ||
| TWI228116B (en) | Monoamine reuptake inhibitors for treatment of CNS disorders | |
| AU2000269268B2 (en) | Bupropion metabolites and methods of their synthesis and use | |
| CN1832734B (zh) | 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘 | |
| CA2498152A1 (en) | Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | |
| KR20250114110A (ko) | 약물 활성의 조절제로서의 부프로피온 | |
| JP2013544850A5 (enExample) | ||
| JPH08208471A (ja) | 薬物反応の増強作用 | |
| JP2016540771A (ja) | セロトニン−ノルアドレナリン再取り込み阻害薬（ｓｎｒｉ）およびシグマ受容体リガンドの組み合わせ | |
| JP2005508872A5 (enExample) | ||
| EP1643985B1 (en) | The combination of a serotonin reuptake inhibitors and agomelatine | |
| WO2016101898A1 (zh) | 3-[(苯并[d][1，3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用 | |
| JP2007523052A (ja) | 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ | |
| JP2010280699A (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| JPWO2020131899A5 (enExample) | ||
| JP2007528892A (ja) | 認知機能の減退を阻止するための複合医薬組成物 | |
| JP2005531594A5 (ja) | 慢性痛の治療用トリプルモノアミン再取り込み阻害剤 | |
| JP2011088919A (ja) | アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物 | |
| TW201124139A (en) | Solid forms of 4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-n, n-diethylbenzamide, compositions thereof, and uses therewith | |
| TW200534848A (en) | 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders | |
| IL282718B1 (en) | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | |
| KR20010099648A (ko) | 신규 조성물 | |
| TW200817003A (en) | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor | |
| CN101189215A (zh) | 苯并氧氮辛因及其治疗用途 | |
| RU2320662C1 (ru) | ЗАМЕЩЕННЫЕ ПИРРОЛО[4,3-b]ИНДОЛЫ, КОМБИНАТОРНАЯ И ФОКУСИРОВАННАЯ БИБЛИОТЕКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |